Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1 Rearranged NSCLC: Case Report

被引:3
作者
Begum, Parvin [1 ]
Cui, Wanyuan [1 ]
Popat, Sanjay [1 ,2 ,3 ]
机构
[1] Royal Marsden NHS Fdn Trust, Lung Unit, London, England
[2] Inst Canc Res, London, England
[3] Royal Marsden Hosp, Lung Unit, Fulham Rd, London SW3 6JJ, England
来源
JTO CLINICAL AND RESEARCH REPORTS | 2022年 / 3卷 / 09期
关键词
Non-small cell lung cancer; ROS1; fusion; ctDNA; Lorlatinib; Case report; ACQUIRED-RESISTANCE; CRIZOTINIB;
D O I
10.1016/j.jtocrr.2022.100376
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ROS1 gene rearrangements occur in 1% to 2% of NSCLC. Acquired "on-target" mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib. Here, we report the first case of a patient with an acquired ROS1 G2101A resistance mutation after first-line crizotinib, who responded to lorlatinib. The response was dramatic but short in duration. (c) 2022 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND li-cense (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).
引用
收藏
页数:4
相关论文
共 5 条
[1]   Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer [J].
Lin, Jessica J. ;
Choudhury, Noura J. ;
Yoda, Satoshi ;
Zhu, Viola W. ;
Johnson, Ted W. ;
Sakhtemani, Ramin ;
Dagogo-Jack, Ibiayi ;
Digumarthy, Subba R. ;
Lee, Charlotte ;
Do, Andrew ;
Peterson, Jennifer ;
Prutisto-Chang, Kylie ;
Malik, Wafa ;
Hubbeling, Harper G. ;
Langenbucher, Adam ;
Schoenfeld, Adam J. ;
Falcon, Christina J. ;
Temel, Jennifer S. ;
Sequist, Lecia, V ;
Yeap, Beow Y. ;
Lennerz, Jochen K. ;
Shaw, Alice T. ;
Lawrence, Michael S. ;
Ou, Sai-Hong Ignatius ;
Hata, Aaron N. ;
Drilon, Alexander ;
Gainor, Justin F. .
CLINICAL CANCER RESEARCH, 2021, 27 (10) :2899-2909
[2]   ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor [J].
Michels, Sebastian Y. F. ;
Scheel, Andreas H. ;
Wuendisch, Thomas ;
Heuckmann, Johannes M. ;
Menon, Roopika ;
Puesken, Michael ;
Kobe, Carsten ;
Pasternack, Helen ;
Heydt, Carina ;
Scheffler, Matthias ;
Fischer, Rieke ;
Schultheis, Anne M. ;
Merkelbach-Bruse, Sabine ;
Heukamp, Lukas ;
Buettner, Reinhard ;
Woelf, Jurgen .
NPJ PRECISION ONCOLOGY, 2017, 1
[3]   US Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors [J].
Papadopoulos, Kyriakos P. ;
Borazanci, Erkut ;
Shaw, Alice T. ;
Katayama, Ryohei ;
Shimizu, Yuki ;
Zhu, Viola W. ;
Sun, Thomas Yang ;
Wakelee, Heather A. ;
Madison, Russell ;
Schrock, Alexa B. ;
Senaldi, Giorgio ;
Nakao, Naoki ;
Hanzawa, Hiroyuki ;
Tachibana, Masaya ;
Isoyama, Takeshi ;
Nakamaru, Kenji ;
Deng, Chenhui ;
Li, Meijing ;
Fan, Frank ;
Zhao, Qinying ;
Gao, Yanfei ;
Seto, Takashi ;
Janne, Pasi A. ;
Ou, Sai-Hong Ignatius .
CLINICAL CANCER RESEARCH, 2020, 26 (18) :4785-4794
[4]   Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer [J].
Song, Ahnah ;
Kim, Tae Min ;
Kim, Dong-Wan ;
Kim, Soyeon ;
Keam, Bhumsuk ;
Lee, Se-Hoon ;
Heo, Dae Seog .
CLINICAL CANCER RESEARCH, 2015, 21 (10) :2379-2387
[5]   PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations [J].
Zou, Helen Y. ;
Li, Qiuhua ;
Engstrom, Lars D. ;
West, Melissa ;
Appleman, Vicky ;
Wong, Katy A. ;
McTigue, Michele ;
Deng, Ya-Li ;
Liu, Wei ;
Brooun, Alexei ;
Timofeevski, Sergei ;
McDonnell, Scott R. P. ;
Jiang, Ping ;
Falk, Matthew D. ;
Lappin, Patrick B. ;
Affolter, Timothy ;
Nichols, Tim ;
Hu, Wenyue ;
Lam, Justine ;
Johnson, Ted W. ;
Smeal, Tod ;
Charest, Al ;
Fantin, Valeria R. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (11) :3493-3498